• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病的自然史:一项脑库研究。

The natural history of Alzheimer's disease: a brain bank study.

作者信息

Jost B C, Grossberg G T

机构信息

Saint Louis University School of Medicine, Division of Geriatric Psychiatry, Missouri, USA.

出版信息

J Am Geriatr Soc. 1995 Nov;43(11):1248-55. doi: 10.1111/j.1532-5415.1995.tb07401.x.

DOI:10.1111/j.1532-5415.1995.tb07401.x
PMID:7594159
Abstract

OBJECTIVE

To define the natural history of Alzheimer's Disease (AD), from time of clinical (presumptive) diagnosis and/or onset of symptoms to death and to describe demographic and clinical characteristics of patients with AD.

DESIGN

Retrospective medical records review.

SETTING

Regional brain bank operated by a university hospital.

PARTICIPANTS

One-hundred randomly selected, autopsy-confirmed Alzheimer's Disease patients.

MEASUREMENTS

All information pertaining to family and clinical history (diagnoses, office visits, hospitalizations), medication use, nutritional status, and clinical testing (laboratory testing, imaging, diagnostics, and psychometric testing) was abstracted. Time of onset for behavioral symptoms (e.g., anxiety, wandering, agitation) and deficits in cognitive function (e.g., recent memory, concentration, language) and activities of daily living (ADL) were also abstracted. Data was collected on-site using a laptop computer and a series of customized data entry spreadsheets. Upon completion of the data abstraction process, data was converted to a database program for query and analysis.

RESULTS

A complete natural history timeline was constructed based on the mean values observed in order to demonstrate important clinical endpoints, namely, diagnosis, institutionalization, and death. The mean time between onset of symptoms and clinical diagnosis was 32.1 months (standard deviation = 37.9 months). The interval between symptom onset and AD diagnosis was longer for patients who were less than 65 at time of diagnosis (mean = 37.6 months), female patients (mean = 34.9 months), and patients with a positive family history of dementia (mean = 37.5 months). The mean age at diagnosis was 74.7 years (standard deviation = 8.6 years), with a range of 52 to 89 years. Most patients were diagnosed between the ages of 70 and 79. Males were diagnosed at an earlier age, 72.8 years, on average, than females, 75.4 years. The mean time to institutionalization from time of clinical diagnosis was 23.9 months (standard deviation = 33.6 months). The average age at institutionalization was 77.6 years, with a minimum of 60 years and a maximum of 92.5 years. Institutionalization occurred 56.5 months after symptom onset, on average. This interval was shorter among patients with a negative family history (mean = 53.1 months) and patients diagnosed after age 65 (mean = 51.6 months). Patients diagnosed before age 65 experienced a significantly greater average time to institutionalization, 94 months (P = .01). Disease duration was measured as time from symptom onset until death. Mean disease duration was 101.3 months, or nearly 8.5 years (standard deviation = 59.2 months). Subgroup analysis showed that disease duration was prolonged in younger onset patients (mean = 129.1 months), females (mean = 107.9 months), and patients with a positive family history of dementia (mean = 106.3 months).

CONCLUSIONS

These data suggest that the typical AD patient is diagnosed 32 months after symptom onset, at the age of 75 years. This patient is institutionalized 25 months after diagnosis, or approximately 57 months after symptom onset at age 78. The patient remains institutionalized for 44 months or, in actuality, until death. Total disease duration for this typical AD patient is just over 101 months, or approximately 8.5 years.

摘要

目的

确定阿尔茨海默病(AD)从临床(推定)诊断时间和/或症状出现到死亡的自然病程,并描述AD患者的人口统计学和临床特征。

设计

回顾性病历审查。

地点

由大学医院运营的地区脑库。

参与者

随机选择的100例经尸检确诊的阿尔茨海默病患者。

测量

提取所有与家族和临床病史(诊断、门诊就诊、住院)、用药情况、营养状况以及临床检查(实验室检查、影像学检查、诊断检查和心理测量学检查)相关的信息。还提取行为症状(如焦虑、徘徊、激越)、认知功能缺陷(如近期记忆、注意力、语言)和日常生活活动(ADL)的发病时间。使用笔记本电脑和一系列定制的数据录入电子表格在现场收集数据。数据提取过程完成后,将数据转换为数据库程序进行查询和分析。

结果

根据观察到的平均值构建了完整的自然病程时间线,以展示重要的临床终点,即诊断、住院和死亡。症状出现至临床诊断的平均时间为32.1个月(标准差 = 37.9个月)。诊断时年龄小于65岁的患者(平均 = 37.6个月)、女性患者(平均 = 34.9个月)以及有痴呆家族史阳性的患者(平均 = 37.5个月),症状出现至AD诊断的间隔时间更长。诊断时的平均年龄为74.7岁(标准差 = 8.6岁),范围为52至89岁。大多数患者在70至79岁之间被诊断。男性的诊断年龄平均为72.8岁,早于女性的75.4岁。从临床诊断到住院的平均时间为23.9个月(标准差 = 33.6个月)。住院时的平均年龄为77.6岁,最小为60岁,最大为92.5岁。平均而言,症状出现后56.5个月住院。在家族史阴性的患者(平均 = 53.1个月)和65岁以后诊断的患者(平均 = 51.6个月)中,这个间隔时间较短。65岁以前诊断的患者平均住院时间显著更长,为94个月(P = 0.01)。疾病持续时间以从症状出现到死亡的时间来衡量。平均疾病持续时间为101.3个月,即近8.5年(标准差 = 59.2个月)。亚组分析表明,发病年龄较小的患者(平均 = 129.1个月)、女性患者(平均 = 107.9个月)以及有痴呆家族史阳性的患者(平均 = 106.3个月),疾病持续时间延长。

结论

这些数据表明,典型的AD患者在症状出现后32个月、75岁时被诊断。该患者在诊断后25个月住院,即症状出现后约57个月、78岁时住院。患者住院44个月,或者实际上一直到死亡。这个典型AD患者的总疾病持续时间刚刚超过101个月,即约8.5年。

相似文献

1
The natural history of Alzheimer's disease: a brain bank study.阿尔茨海默病的自然史:一项脑库研究。
J Am Geriatr Soc. 1995 Nov;43(11):1248-55. doi: 10.1111/j.1532-5415.1995.tb07401.x.
2
The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study.阿尔茨海默病精神症状的演变:一项自然史研究。
J Am Geriatr Soc. 1996 Sep;44(9):1078-81. doi: 10.1111/j.1532-5415.1996.tb02942.x.
3
Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease.创伤性脑损伤病史与尸检确诊的阿尔茨海默病患者痴呆发病年龄提前有关。
Neuropsychology. 2018 May;32(4):410-416. doi: 10.1037/neu0000423. Epub 2018 Feb 1.
4
5
Behavioral disturbances in Alzheimer's disease: a non-pharmacological therapeutic approach.阿尔茨海默病中的行为障碍:一种非药物治疗方法。
Arch Gerontol Geriatr Suppl. 2004(9):379-86. doi: 10.1016/j.archger.2004.04.048.
6
[Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].[阿尔茨海默病患者长期机构化的预测因素:照顾者负担的作用]
No To Shinkei. 2002 Sep;54(9):812-8.
7
[Clinical presentation of Moroccan cases with Alzheimer's disease].[摩洛哥阿尔茨海默病病例的临床表现]
Encephale. 2014 Dec;40(6):481-6. doi: 10.1016/j.encep.2014.06.006. Epub 2014 Aug 12.
8
Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.阿尔茨海默病新诊断患者的经济负担、死亡率和住院率。
J Alzheimers Dis. 2018;61(1):185-193. doi: 10.3233/JAD-170518.
9
Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.临床实践中的早发性与晚发性阿尔茨海默病:3 年的认知和总体结局。
Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.
10
Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer's Disease: Retrospective Medical Record Review Study and a Nested Case-control Design.在阿尔茨海默病临床诊断之前识别体征和症状模式:回顾性病历审查研究及巢式病例对照设计
Curr Alzheimer Res. 2018;15(8):723-730. doi: 10.2174/1567205015666180404155358.

引用本文的文献

1
Sex-specific transcriptomic profiling reveals key players in bone loss associated with Alzheimer's disease.性别特异性转录组分析揭示了与阿尔茨海默病相关的骨质流失的关键因素。
Geroscience. 2025 Jan 29. doi: 10.1007/s11357-025-01535-7.
2
Dementia in People with Severe/Profound Intellectual (And Multiple) Disabilities, and Its Natural History.重度/极重度智力(及多重)残疾者的痴呆症及其自然史
J Ment Health Res Intellect Disabil. 2023 Jul 27;17(1):1-28. doi: 10.1080/19315864.2023.2240734. eCollection 2024.
3
Mathematical modelling of Alzheimer's disease biomarkers: Targeting Amyloid beta, Tau protein, Apolipoprotein E and Apoptotic pathways.
阿尔茨海默病生物标志物的数学建模:针对淀粉样β蛋白、 Tau蛋白、载脂蛋白E和凋亡途径
Am J Transl Res. 2024 Jul 15;16(7):2777-2792. doi: 10.62347/UJQF5204. eCollection 2024.
4
Lecanemab: A Hopeful Alzheimer's Disease Treatment.乐卡奈单抗:一种有前景的阿尔茨海默病治疗药物。
Ann Neurosci. 2024 Apr;31(2):83-85. doi: 10.1177/09727531231189925. Epub 2023 Nov 3.
5
Basal lamina changes in neurodegenerative disorders.基底膜在神经退行性疾病中的变化。
Mol Neurodegener. 2021 Dec 7;16(1):81. doi: 10.1186/s13024-021-00502-y.
6
Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer's Disease? A Systematic Review.血小板淀粉样前体蛋白加工:它是探索阿尔茨海默病病理生理学的工具吗?一项系统评价。
Life (Basel). 2021 Jul 26;11(8):750. doi: 10.3390/life11080750.
7
Towards Computer-Based Automated Screening of Dementia Through Spontaneous Speech.迈向基于计算机的通过自发语音进行痴呆症自动筛查
Front Psychol. 2021 Feb 12;11:623237. doi: 10.3389/fpsyg.2020.623237. eCollection 2020.
8
A Comprehensive Analysis Identified Hub Genes and Associated Drugs in Alzheimer's Disease.一项综合分析确定了阿尔茨海默病的枢纽基因和相关药物。
Biomed Res Int. 2021 Jan 9;2021:8893553. doi: 10.1155/2021/8893553. eCollection 2021.
9
The Role of Physical Fitness in Cognitive-Related Biomarkers in Persons at Genetic Risk of Familial Alzheimer's Disease.体能在有家族性阿尔茨海默病遗传风险人群认知相关生物标志物中的作用
J Clin Med. 2019 Oct 7;8(10):1639. doi: 10.3390/jcm8101639.
10
Insoluble Aβ overexpression in an knock-in mouse model alters microstructure and gamma oscillations in the prefrontal cortex, affecting anxiety-related behaviours.在 knock-in 小鼠模型中过度表达不可溶的 Aβ 会改变前额叶皮层的微观结构和γ 振荡,从而影响与焦虑相关的行为。
Dis Model Mech. 2019 Sep 24;12(9):dmm040550. doi: 10.1242/dmm.040550.